TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26825258

Group type: EXPERIMENTAL
Intervention: Drospirenone-containing combined oral contraceptives (DRSP)
Number of subjects: 59510

Group type: COMPARATOR
Intervention: Levonorgestrel-containing OCs (LNG)
Number of subjects: 59510

Group type: COMPARATOR
Intervention: Other OCs
Number of subjects: 59510
Study: 24647863

Group type: EXPERIMENTAL
Intervention: Elastic tubing training
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional resistance training
Number of subjects: 49
Study: 22047681

Group type: EXPERIMENTAL
Intervention: L-carnitine 4 g/day + Celecoxib 300 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: L-carnitine 4 g/day + celecoxib 300 mg/day + megestrol acetate 320 mg/day
Number of subjects: 60
Study: 19679216

Group type: EXPERIMENTAL
Intervention: RIX4414 (Rotarix)
Number of subjects: 10708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10708
Study: 22075812

Group type: EXPERIMENTAL
Intervention: Suture technique (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Suture-plus-graft technique (group B)
Number of subjects: 60
Study: 16053010

Group type: EXPERIMENTAL
Intervention: Daily renal multivitamin containing folate (FA), vitamin B6 and B12 (5 mg, 10 mg and 0.4 mg respectively)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Supraphysiological daily doses (15 mg, 100 mg and 1 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group from the general population (N = 276)
Number of subjects: 60
Study: 11812753

Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (2,550 mg/day)
Number of subjects: 0
Study: 10363745

Group type: EXPERIMENTAL
Intervention: IGF‐I (8 microg kg(‐1) h(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 7
Study: 7491880

Group type: COMPARATOR
Intervention: 5 g fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 g fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 g fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 g fat plus 50 g fructose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A (36 mg, or 120,000 U retinol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher fat loads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sf 20-400 lipoprotein fraction
Number of subjects: 0
Study: 1828420

Group type: EXPERIMENTAL
Intervention: Amlodipine 1.25 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All amlodipine doses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amlodipine (all doses)
Number of subjects: 60
Study: 6791200

Group type: EXPERIMENTAL
Intervention: 1 mg haloperidol IM
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29925934

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine (CisGem)
Number of subjects: 117
Study: 27601428

Group type: EXPERIMENTAL
Intervention: Transfemoral (TF) TAVR
Number of subjects: 2621

Group type: EXPERIMENTAL
Intervention: Transapical (TA) TAVR
Number of subjects: 2621
Study: 24613084

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 2499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499

Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis
Number of subjects: 2499
Study: 22191384

Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (daily oral intake)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physical exercise and Mediterranean diet (Control group)
Number of subjects: 80
Study: 20696032

Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 100
Study: 18214607

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (5,000 IU) administered subcutaneously 20 to 30 min before ERCP
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (saline solution 0.5 ml) administered subcutaneously 20 to 30 min before ERCP
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (5,000 IU)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (saline solution 0.5 ml)
Number of subjects: 105
Study: 15845568

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with concurrent carboplatin 30 mg/m² per fraction up to the first 20 fractions.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone with irradiation of 60 Gy.
Number of subjects: 46
Study: 12826150

Group type: EXPERIMENTAL
Intervention: Simulect (20 mg, 30 minutes before reperfusion and 4 days after transplantation) and steroids
Number of subjects: 45
Study: 10582540

Group type: EXPERIMENTAL
Intervention: Verapamil (VER) administered acutely
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Verapamil (VER) administered intravenously (IV)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Different oral formulations of Verapamil (VER)
Number of subjects: 34
Study: 8945114

Group type: EXPERIMENTAL
Intervention: Person-centered counseling intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 73
Study: 1768630

Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status (KPS) scale
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: ECOG Performance Status (EPS) scale
Number of subjects: 209
Study: 7225473

Group type: EXPERIMENTAL
Intervention: Sublingual exposure to allergens
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30909252

Group type: EXPERIMENTAL
Intervention: PPV coaching during neonatal bag-mask ventilation
Number of subjects: 0
Study: 29649997

Group type: COMPARATOR
Intervention: Minimal Intervention Group (MIG; no feedback)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Coaching Group (CoachG; feedback on daily steps, MVPA, total EE with need supportive coaching)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Coaching Group (CoachG)
Number of subjects: 227
Study: 27646843

Group type: EXPERIMENTAL
Intervention: Ricolinostat 160 mg once daily on days 1–21 of a 28 day cycle, in combination with lenalidomide 25 mg and dexamethasone 40 mg.
Number of subjects: 38
Study: 23464813

Group type: EXPERIMENTAL
Intervention: Oral pregabalin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transdermal fentanyl
Number of subjects: 120
Study: 22795275

Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: PVI + CFE
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: PVI + Lines
Number of subjects: 549
Study: 19893505

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Casein supplementation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Glucose supplementation
Number of subjects: 70
Study: 18570844

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac anal suppository after surgery
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group without diclofenac
Number of subjects: 157
Study: 15849209

Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 400 microg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine 0.5%
Number of subjects: 80
Study: 12422496

Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 fatty acid product)
Number of subjects: 0
Study: 12378740

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7642049

Group type: EXPERIMENTAL
Intervention: Physical training (Group A)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Physical training (Group A) in inferior MI
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Physical training (Group A) in anterior MI
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison of occluded vs patent infarct-related coronary artery
Number of subjects: 104

Group type: COMPARATOR
Intervention: Comparison of patients with larger vs smaller EDVi after 3 months
Number of subjects: 104
Study: 2613203

Group type: COMPARATOR
Intervention: Methotrexate and 5‐fluorouracil
Number of subjects: 559

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 559
Study: 797543

Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active corticosteroid comparison drug
Number of subjects: 60
Study: 30781962

Group type: EXPERIMENTAL
Intervention: Primary sanation of the abdominal cavity (toilet, peroperative lavage, postoperative drainage)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Postoperative continuous lavage (irrigation with saline or another solution over 24-48 hours)
Number of subjects: 55
Study: 27796035

Group type: EXPERIMENTAL
Intervention: Enhanced medication plan with graphical and textual information on drug handling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Simple medication plan with standard information
Number of subjects: 120
Study: 26193215

Group type: EXPERIMENTAL
Intervention: VEGF‐A
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ORM‐1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ORM‐1 and VEGF‐A correlation
Number of subjects: 36
Study: 23273975

Group type: EXPERIMENTAL
Intervention: Glyburide therapy (dose of 3.3±2.1 mg/day for R230C vs 6.3±5 mg/day for R230R)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (R230R participants)
Number of subjects: 4
Study: 21067858

Group type: EXPERIMENTAL
Intervention: P and 2mg E2
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: P and 4mg E2
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: P and 6mg E2
Number of subjects: 285
Study: 19906561

Group type: EXPERIMENTAL
Intervention: Capecitabine and docetaxel followed by cyclophosphamide, epirubicin, and capecitabine (capecitabine group, n=753)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil (control group, n=747)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Capecitabine group
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1500
Study: 17289173

Group type: EXPERIMENTAL
Intervention: Abciximab-coated stent
Number of subjects: 138

Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Both groups (abciximab-coated stent and BMS)
Number of subjects: 138
Study: 14763958

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 11290867

Group type: EXPERIMENTAL
Intervention: Ifosfamide 1500 mg/m2 in 1000 ml saline infused over 60 min, mesna 20% of total dose of ifosfamide in three doses for 3 days, mitoxantrone 12 mg/m2 on day 1; treatment repeated every 4 weeks for up to six cycles.
Number of subjects: 22
Study: 9602591

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 0
Study: 8014304

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 5
Study: 2682243

Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin (0.3 microgram per kilogram of body weight)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 150
Study: 4836732

Group type: EXPERIMENTAL
Intervention: Fast Medium Slow (F M S) pace
Number of subjects: 8

Group type: COMPARATOR
Intervention: Slow Medium Slow pace
Number of subjects: 8
Study: 31783161

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) mediated antimicrobial photodynamic therapy (aPDT) along with scaling and root planing (SRP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 29
Study: 31293563

Group type: EXPERIMENTAL
Intervention: Subdose 10,447 IU
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Subdose 3,013 IU
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Subdose 587 IU
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Subdose 158 IU
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Subdose 31 IU
Number of subjects: 144

Group type: COMPARATOR
Intervention: Full dose 27,476 IU
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All subdoses (10,447 IU, 3,013 IU, 587 IU, 158 IU, 31 IU)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Subdoses above 587 IU
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Subdoses (except for 31 IU)
Number of subjects: 144
Study: 28379980

Group type: EXPERIMENTAL
Intervention: Active tsDCS
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 12
Study: 26887214

Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Acupuncture (control)
Number of subjects: 200
Study: 24348029

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) at 30 Hz and 3.2 g for 5 minutes, three times per week for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison between WBV and control groups
Number of subjects: 28
Study: 22186118

Group type: EXPERIMENTAL
Intervention: Mildronate 100 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Mildronate 300 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Mildronate 1000 mg
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Mildronate 3000 mg
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study: 19226229

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil anesthesia with supplemental muscle relaxants (Group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Propofol and remifentanil anesthesia without supplemental muscle relaxants (Group B)
Number of subjects: 56
Study: 16504757

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (Arm A): 500 mg/m2 5-fluorouracil, 12 mg/m2 mitoxantrone, and 500 mg/m2 cyclophosphamide with concomitant radiotherapy (50 Gy +/- 10-20-Gy boost)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy followed by radiotherapy (Arm B): 500 mg/m2 5-fluorouracil, 60 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide with subsequent radiotherapy
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (Arm A)
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy (Arm A)
Number of subjects: 638
Study: 11967036

Group type: EXPERIMENTAL
Intervention: AM3 (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Number of subjects: 269
Study: 10754365

Group type: EXPERIMENTAL
Intervention: 200 mg i.v. erythromycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7550181

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: EuroQol
Number of subjects: 332

Group type: COMPARATOR
Intervention: Rosser classification and index
Number of subjects: 332
Study: 1709338

Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study: 6788400

Group type: EXPERIMENTAL
Intervention: i.v. encainide 75 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: oral encainide 75 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 6380827

Group type: EXPERIMENTAL
Intervention: Adenoidectomy and insertion of 1 grommet on a side chosen at random
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control side (no grommet)
Number of subjects: 54
Study: 29193211

Group type: EXPERIMENTAL
Intervention: TXA 1g intravenous bolus followed by continuous infusion of TXA 1g over 8 hours
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 27765184

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24993769

Group type: EXPERIMENTAL
Intervention: Vasopressin (0-0.06 U/min)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Noradrenaline (0-12 µg/min)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenous bolus six-hourly)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Vasopressin or Noradrenaline
Number of subjects: 412
Study: 22576032

Group type: EXPERIMENTAL
Intervention: Resting Heart System (RHS; Medtronic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional CPB without cardiotomy suction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional CPB with cardiotomy suction
Number of subjects: 60
Study: 20032699

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6, 1.2, 2.4 ng/ml)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propofol (1, 2, 4 microg/ml)
Number of subjects: 11
Study: 18754983

Group type: EXPERIMENTAL
Intervention: Perineal warm packs
Number of subjects: 697

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 697
Study: 15957828

Group type: EXPERIMENTAL
Intervention: Purified Xuefu Capsule (PXC) with conventional western medicine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional western medicine alone
Number of subjects: 92
Study: 11989834

Group type: EXPERIMENTAL
Intervention: Prucalopride 1 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 9872814

Group type: EXPERIMENTAL
Intervention: Inhaled PGE2 (100 microgram)
Number of subjects: 8
Study: 8650026

Group type: EXPERIMENTAL
Intervention: Auditory Brainstem Response (ABR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pure Tone Audiometry
Number of subjects: 60
Study: 2169638

Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil (as a source of gamma-linolenic acid)
Number of subjects: 0
Study: 7312535

Group type: EXPERIMENTAL
Intervention: Content presented aurally at an expanded rate of speech
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Content presented aurally at a normal rate of speech
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Content presented aurally at a compressed rate of speech
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Historical content presented at variable rates
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biological content presented at variable rates
Number of subjects: 60
Study: 31995813

Group type: EXPERIMENTAL
Intervention: Modafinil (single-dose, 200 mg)
Number of subjects: 0
Study: 31283407

Group type: EXPERIMENTAL
Intervention: Myeloid-style consolidation chemotherapy (ADE and MAE)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Lymphoid-style consolidation chemotherapy (IB)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: High-risk group with intention to undergo stem-cell transplantation (SCT)
Number of subjects: 651
Study: 28214913

Group type: EXPERIMENTAL
Intervention: BNO 1016 (Sinupret extract)
Number of subjects: 929

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 929
Study: 26552423

Group type: EXPERIMENTAL
Intervention: Non-pharmacological self-management modular program group intervention along with standard of care
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard-of-care treatment only
Number of subjects: 206
Study: 24126178

Group type: EXPERIMENTAL
Intervention: Flaxseed (30 g of milled flaxseed daily for 6 months)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (daily ingestion of placebo for 6 months)
Number of subjects: 110
Study: 21701431

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 237

Group type: COMPARATOR
Intervention: Endometrial Ablation (EA)
Number of subjects: 237
Study: 19388862

Group type: EXPERIMENTAL
Intervention: Woolen underwear and woolen bedding (woolen bed liner, woolen quilt, and pillow) for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified what they received)
Number of subjects: 50
Study: 17433313

Group type: EXPERIMENTAL
Intervention: Recombinant hCG (r-hCG)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Urinary hCG (u-hCG)
Number of subjects: 284
Study: 15369762

Group type: EXPERIMENTAL
Intervention: Saliva from patients with diabetes mellitus
Number of subjects: 52

Group type: COMPARATOR
Intervention: Saliva from healthy control subjects incubated with hypochloric acid
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Presence of advanced glycation endproducts in patients with diabetes mellitus
Number of subjects: 52
Study: 12445026

Group type: EXPERIMENTAL
Intervention: V11294A (300 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10427934

Group type: EXPERIMENTAL
Intervention: WHO/UNICEF 40-hour course 'Breastfeeding counselling: a training course'
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 8551488

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 1697284

Group type: EXPERIMENTAL
Intervention: 5% human albumin (HA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HAES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (HA and HAES)
Number of subjects: 60
Study: 7009887

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 57

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole combination
Number of subjects: 57
Study: 30413516

Group type: EXPERIMENTAL
Intervention: ActWELL weight management intervention (diet, physical activity, behaviour change techniques)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: ActWELL weight management intervention
Number of subjects: 414
Study: 27050206

Group type: EXPERIMENTAL
Intervention: Radiation therapy plus chemotherapy (procarbazine, CCNU, and vincristine)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 251